Literature DB >> 26786016

Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.

Anders N Kristoffersson1, Pascale David-Pierson2, Neil J Parrott2, Olaf Kuhlmann2, Thierry Lave2, Lena E Friberg3, Elisabet I Nielsen3.   

Abstract

PURPOSE: Antibiotic dose predictions based on PK/PD indices rely on that the index type and magnitude is insensitive to the pharmacokinetics (PK), the dosing regimen, and bacterial susceptibility. In this work we perform simulations to challenge these assumptions for meropenem and Pseudomonas aeruginosa.
METHODS: A published murine dose fractionation study was replicated in silico. The sensitivity of the PK/PD index towards experimental design, drug susceptibility, uncertainty in MIC and different PK profiles was evaluated.
RESULTS: The previous murine study data were well replicated with fT > MIC selected as the best predictor. However, for increased dosing frequencies fAUC/MIC was found to be more predictive and the magnitude of the index was sensitive to drug susceptibility. With human PK fT > MIC and fAUC/MIC had similar predictive capacities with preference for fT > MIC when short t1/2 and fAUC/MIC when long t1/2.
CONCLUSIONS: A longitudinal PKPD model based on in vitro data successfully predicted a previous in vivo study of meropenem. The type and magnitude of the PK/PD index were sensitive to the experimental design, the MIC and the PK. Therefore, it may be preferable to perform simulations for dose selection based on an integrated PK-PKPD model rather than using a fixed PK/PD index target.

Entities:  

Keywords:  antibiotic; dose selection; meropenem; pharmacometric; pseudomonas aeruginosa

Mesh:

Substances:

Year:  2016        PMID: 26786016     DOI: 10.1007/s11095-016-1856-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

1.  Prevention of resistance: a goal for dose selection for antimicrobial agents.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

Review 2.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

3.  Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Authors:  Ami F Mohamed; Ilias Karaiskos; Diamantis Plachouras; Matti Karvanen; Konstantinos Pontikis; Britt Jansson; Evangelos Papadomichelakis; Anastasia Antoniadou; Helen Giamarellou; Apostolos Armaganidis; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 4.  In vitro pharmacodynamic models to determine the effect of antibacterial drugs.

Authors:  Julia Gloede; Christian Scheerans; Hartmut Derendorf; Charlotte Kloft
Journal:  J Antimicrob Chemother       Date:  2009-12-21       Impact factor: 5.790

5.  A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.

Authors:  Yoshiaki Kitamura; Kenta Yoshida; Makiko Kusama; Yuichi Sugiyama
Journal:  Drug Metab Pharmacokinet       Date:  2014-07-08       Impact factor: 3.614

6.  Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.

Authors:  G L Drusano; T P Lodise; D Melnick; W Liu; A Oliver; A Mena; B VanScoy; A Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

7.  Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.

Authors:  Ami F Mohamed; Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

8.  Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.

Authors:  Ami F Mohamed; Anders N Kristoffersson; Matti Karvanen; Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  J Antimicrob Chemother       Date:  2016-02-04       Impact factor: 5.790

9.  Meropenem pharmacokinetics in the newborn.

Authors:  John N van den Anker; Pavla Pokorna; Martina Kinzig-Schippers; Jirina Martinkova; Ronald de Groot; G L Drusano; Fritz Sorgel
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

10.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more
  25 in total

Review 1.  Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.

Authors:  Sofie Dhaese; Aaron Heffernan; David Liu; Mohd Hafiz Abdul-Aziz; Veronique Stove; Vincent H Tam; Jeffrey Lipman; Jason A Roberts; Jan J De Waele
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

Review 2.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

Review 3.  Translational PK/PD of anti-infective therapeutics.

Authors:  Chetan Rathi; Richard E Lee; Bernd Meibohm
Journal:  Drug Discov Today Technol       Date:  2016-10-28

4.  Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Authors:  M A Zuur; S Ghimire; M S Bolhuis; A M A Wessels; R van Altena; W C M de Lange; J G W Kosterink; D J Touw; T S van der Werf; O W Akkerman; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.

Authors:  Pelle Hanberg; Kristina Öbrink-Hansen; Anders Thorsted; Mats Bue; Mikkel Tøttrup; Lena E Friberg; Tore Forsingdal Hardlei; Kjeld Søballe; Jakob Gjedsted
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Semimechanistic Modeling of Eravacycline Pharmacodynamics Using In Vitro Time-Kill Data with MIC Incorporated in an Adaptive Resistance Function.

Authors:  Ken Nguyen; Timothy J Bensman; Xiaohui Tracey Wei; Jason N Moore
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

7.  Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.

Authors:  James Albiero; Josmar Mazucheli; Juliana Pimenta Dos Reis Barros; Marcia Maria Dos Anjos Szczerepa; Sheila Alexandra Belini Nishiyama; Floristher Elaine Carrara-Marroni; Serubbabel Sy; Matthew Fidler; Sherwin K B Sy; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

8.  Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.

Authors:  Rajbharan Yadav; Jürgen B Bulitta; Jiping Wang; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

9.  Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis.

Authors:  Laurynas Mockeliunas; Lina Keutzer; Marieke G G Sturkenboom; Mathieu S Bolhuis; Lotte M G Hulskotte; Onno W Akkerman; Ulrika S H Simonsson
Journal:  Pharmaceutics       Date:  2022-03-30       Impact factor: 6.525

Review 10.  En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.

Authors:  Pierre-Louis Toutain; Alain Bousquet-Mélou; Peter Damborg; Aude A Ferran; Dik Mevius; Ludovic Pelligand; Kees T Veldman; Peter Lees
Journal:  Front Microbiol       Date:  2017-12-15       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.